Key facts
- It has raised $14.8M; the latest was Later Stage VC in Jan 2025.
- Notable investors include CICC Capital, Beijing Bohua Capital, Nanjing Industrial Development Fund, RayStone Capital, Fosun Pharma — 9 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 9 names
- ·Watchlist + deal alerts for SYSDIAGNO
- ·The full record, as it builds
Funding rounds
No funding rounds for SYSDIAGNO are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About SYSDIAGNO
Manufacturer of in vitro diagnostic kits designed for early detection of liver cancer in patients with chronic hepatitis B and cirrhosis. The company offers a platform utilizing glycomics-based detection technology, which analyzes serum glycan profiles through capillary electrophoresis and AI-driven data interpretation, enabling healthcare providers to achieve higher sensitivity and specificity in liver cancer diagnostics, particularly in cases where traditional markers are insufficient.
- Sector
- Healthcare
- HQ
- Nanjing, China
- Founded
- 2012
- Employees
- 20
- Ownership
- Privately Held (backing)
SYSDIAGNO doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in SYSDIAGNO shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on SYSDIAGNO in its N-PORT filings yet. We sweep new filings monthly.